137 related articles for article (PubMed ID: 25173576)
41. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.
Di Biagio A; Ricci E; Viscoli C; Mesini A; Menzaghi B; Carenzi L; Orofino G; Parruti G; Martinelli C; Madeddu G; De Socio GV; Franzetti M; Quirino T; Bonfanti P;
Curr HIV Res; 2013 Apr; 11(3):179-86. PubMed ID: 23432466
[TBL] [Abstract][Full Text] [Related]
42. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
Infez Med; 2015 Mar; 23(1):36-43. PubMed ID: 25819049
[TBL] [Abstract][Full Text] [Related]
43. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
[TBL] [Abstract][Full Text] [Related]
44. The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
Young J; Scherrer AU; Calmy A; Tarr PE; Bernasconi E; Cavassini M; Hachfeld A; Vernazza P; Günthard HF; Bucher HC;
Antivir Ther; 2019; 24(5):343-353. PubMed ID: 30985290
[TBL] [Abstract][Full Text] [Related]
45. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Marchetti G; Rusconi S; Gori A; Nozza S; Lichtner M; Antinori A; Cossarizza A; d'Arminio Monforte A;
BMC Med; 2018 May; 16(1):79. PubMed ID: 29807541
[TBL] [Abstract][Full Text] [Related]
46. Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients.
Nozza S; Pogliaghi M; Chiappetta S; Spagnuolo V; Fontana G; Razzari C; Tambussi G; Faioni EM
PLoS One; 2012; 7(6):e37032. PubMed ID: 22715361
[TBL] [Abstract][Full Text] [Related]
47. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
[TBL] [Abstract][Full Text] [Related]
48. Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients.
Pulido I; Genebat M; Alvarez-Rios AI; De Pablo-Bernal RS; Rafii-El-Idrissi Benhnia M; Pacheco YM; Ruiz-Mateos E; Leal M
Viral Immunol; 2016 Oct; 29(8):471-477. PubMed ID: 27689417
[TBL] [Abstract][Full Text] [Related]
49. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
Saumoy M; Llibre JM; Terrón A; Knobel H; Arribas JR; Domingo P; Arroyo-Manzano D; Rivero A; Moreno S; Podzamczer D
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):29-32. PubMed ID: 27250802
[TBL] [Abstract][Full Text] [Related]
50. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.
Bastard JP; Fellahi S; Couffignal C; Raffi F; Gras G; Hardel L; Sobel A; Leport C; Fardet L; Capeau J;
J Antimicrob Chemother; 2015; 70(6):1816-24. PubMed ID: 25733587
[TBL] [Abstract][Full Text] [Related]
51. Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study.
Vallejo A; Molano M; Monsalvo-Hernando M; Hernández-Walias F; Fontecha-Ortega M; Casado JL
HIV Med; 2019 Sep; 20(8):555-560. PubMed ID: 31131528
[TBL] [Abstract][Full Text] [Related]
52. Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts.
Sipsas NV; Sfikakis PP; Kontos A; Kordossis T
Clin Diagn Lab Immunol; 2002 May; 9(3):558-61. PubMed ID: 11986259
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study.
Jianu C; Itu-Mureşan C; Drugan C; Filipescu I; Topan AV; Jianu ME; Morar II; Bolboacă SD
PLoS One; 2021; 16(11):e0260007. PubMed ID: 34784398
[TBL] [Abstract][Full Text] [Related]
54. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy.
Jong E; Louw S; Meijers JC; de Kruif MD; ten Cate H; Büller HR; Mulder JW; van Gorp EC
AIDS Patient Care STDS; 2009 Dec; 23(12):1001-7. PubMed ID: 19929230
[TBL] [Abstract][Full Text] [Related]
55. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.
Lombardi F; Belmonti S; Borghetti A; Ciccullo A; Baldin G; Cauda R; Fabbiani M; Di Giambenedetto S
HIV Res Clin Pract; 2019 Jun; 20(3):92-98. PubMed ID: 31478469
[No Abstract] [Full Text] [Related]
56. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
Massanella M; Ouchi D; Marfil S; Llibre JM; Puertas MC; Buzón MJ; Richman DD; Orna E; Stevenson M; Gatell JM; Domingo P; Negredo E; Martinez-Picado J; Clotet B; Blanco J
PLoS One; 2014; 9(12):e114142. PubMed ID: 25462535
[TBL] [Abstract][Full Text] [Related]
57. Inflammatory Markers after Switching to a Dual Drug Regimen in HIV-Infected Subjects: A Two-Year Follow-Up.
Vassallo M; Durant J; Fabre R; Lotte L; Sindt A; Puchois A; De Monte A; Cezar R; Corbeau P; Pradier C
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632669
[TBL] [Abstract][Full Text] [Related]
58. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Lê MP; Soulié C; Assoumou L; Valantin MA; Duvivier C; Chas J; Ponscarme D; Marcelin AG; Calvez V; Katlama C; Peytavin G;
J Antimicrob Chemother; 2015 Aug; 70(8):2418-20. PubMed ID: 25917348
[No Abstract] [Full Text] [Related]
59. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.
Achhra AC; Boyd MA
AIDS Res Ther; 2013 Dec; 10(1):33. PubMed ID: 24330617
[TBL] [Abstract][Full Text] [Related]
60. Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy.
Steel HC; Venter WDF; Theron AJ; Anderson R; Feldman C; Arulappan N; Rossouw TM
Front Immunol; 2020; 11():594110. PubMed ID: 33584658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
